Long-term safety and efficacy of fluticasone/formoterol combination therapy in Asthma

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 26, Issue 4, 2013, Pages 190-199

  Mansur, Adel H ^a   Kaiser, Kirsten ^b  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b SkyePharma   (Switzerland)

Author keywords

asthma; combination therapy; fluticasone propionate; flutiform ; formoterol fumarate

Indexed keywords

FLUTICASONE PROPIONATE PLUS FORMOTEROL FUMARATE;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; HUMAN; HYPERTENSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; OPEN STUDY; PHARYNGITIS; RHINOPHARYNGITIS; RISK ASSESSMENT; SIDE EFFECT; THROMBOCYTE COUNT;

EID: 84871649120     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2012.0977     Document Type: Article

References (61)

1. Masoli M, Fabian D, Holt S, and Beasley R: Global burden of asthma, a report for the Global Initiative for Asthma. 2004. Available from: http://www.ginasthma.org. Accessed January 2011.
2. Global Initiative for Asthma Report: GINA Report. Global strategy for asthma management and prevention. 2009. Available from: http://www.ginasthma. org. Accessed January 2011.
3. Murphy DM, and O'Byrne PM: Recent advances in the pathophysiology of asthma. Chest. 2010;137:1417-1426.
4. Naedele-Risha R, Dorinsky P, and Craig TJ: Dual components of optimal asthma therapy: scientific and clinical rationale for the use of long-acting beta-agonists with inhaled corticosteroids. J Am Osteopath Assoc. 2001;101:526-533. (Pubitemid 32880282)
5. Lö tvall J, and Ankerst J: Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients. Respir Med. 2008;102:449-456.
6. Barnes PJ: Scientific rationale for using a single inhaler for asthma control. Eur Respir J. 2007;29:587-595. (Pubitemid 46372109)
7. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, and Ullman A: Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997;337: 1405-1411.
8. Greening AP, Ind PW, Northfield M, and Shaw G: Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet. 1994;344:219-224. (Pubitemid 24229008)
9. Woolcock A, Lundback B, Ringdal N, and Jacques LA: Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996;153:1481-1488. (Pubitemid 26141329)
10. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, and Tattersfield A: Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164(8 Pt 1):1392-1397. (Pubitemid 33124016)
11. Thomas M, Kay S, Pike J, Williams A, Rosenzweig JR, Hillyer EV, and Price D: The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim Care Respir J. 2009;18:41-49.
12. Barnes PJ: Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J. 2002;19:182-191. (Pubitemid 34105586)
13. Roth M, Zhong J, S'ng C, and Tamm M: Effect of fluticasone and formoterol combination therapy on airway remodeling. [Abstract] Presented at European Respiratory Society Congress, Amsterdam, The Netherlands, 2011. Eur Respir J. 2011;38(Suppl 55):307s.
14. Roth M, Zhong J, S'ng C, and Tamm M: The long-acting b2-agonist formoterol re-establishes the anti-proliferative effect of glucocorticoids in asthmatic airway smooth muscle cells (ASMC). [Abstract] Presented at European Respiratory Society Congress, Amsterdam, The Netherlands, 2011. Eur Respir J. 2011;38(Suppl 55):612s.
15. Usmani OS, Ito K, Maneechotesuwan K, Ito M, Johnson M, Barnes PJ, and Adcock IM: Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med. 2005;172:704-712. (Pubitemid 41324225)
16. Bateman ED, Britton M, Carrillo J, Almeida J, and Wixon C: Salmeterol/fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma. Clin Drug Investig. 1998;16:193-201. (Pubitemid 28477069)
17. Kavuru M, Melamed J, Gross G, Laforce C, House K, Prillaman B, Baitinger L, Woodring A, and Shah T: Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2000;105(6 Pt 1):1108-1116. (Pubitemid 30418788)
18. Stallberg B, Olsson P, Jorgensen LA, Lindarck N, and Ekstrom T: Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract. 2003;57:656-661. (Pubitemid 37428199)
19. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, and Pedersen SE: Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170:836-844. (Pubitemid 39346477)
20. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, Ekström T, and Bateman ED: Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;171:129-136. (Pubitemid 40105411)
21. Huchon G, Magnussen H, Chuchalin A, Dymek L, Gonod FB, and Bousquet J: Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med. 2009;103:41-49.
22. Partridge MR, van der Molen T, Myrseth SE, and Busse WW: Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006;6:13.
23. Accordini S, Bugiani M, Arossa W, Gerzeli S, Marinoni A, Olivieri M, Pirina P, Carrozzi L, Dallari R, De Togni A, and de Marco R: Poor control increases the economic cost of asthma. A multicentre population-based study. Int Arch Allergy Immunol. 2006;141:189-198. (Pubitemid 44413295)
24. Cazzoletti L, Marcon A, Janson C, Corsico A, Jarvis D, Pin I, Accordini S, Almar E, Bugiani M, Carolei A, Cerveri I, Duran-Tauleria E, Gislason D, Gulsvik A, Jogi R, Marinoni A, Martinez-Moratalla J, Vermeire P, and de Marco R: Asthma control in Europe: a real-world evaluation based on an international population-based study. J Allergy Clin Immunol. 2007;120:1360-1367. (Pubitemid 350225685)
25. Demoly P, Paggiaro P, Plaza V, Bolge SC, Kannan H, Sohier B, and Adamek L: Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK. Eur Respir Rev. 2009;18:105-112.
26. Virchow JC, Crompton GK, Dal Negro R, Pedersen S, Magnan A, Seidenberg J, and Barnes PJ: Importance of inhaler devices in the management of airway disease. Respir Med. 2008;102:10-19. (Pubitemid 350161842)
27. Leidy NK, Gutierrez B, Lampl K, Uryniak T, and O'Brien CD: Can patients with asthma feel inhaler therapy working right away? Two clinical trials testing the effect of timing of assessment on patient perception. J Asthma. 2009;46:1006-1012.
28. Kraft M: The distal airways: are they important in asthma? Eur Respir J. 1999;14:1403-1417. (Pubitemid 30019540)
29. Kraft M: Part III: Location of asthma inflammation and the distal airways: clinical implications. Curr Med Res Opin. 2007;23 Suppl 3:S21-S27. (Pubitemid 350033430)
30. Burgel PR, de Blic J, Chanez P, Delacourt C, Devillier P, Didier A, Dubus JC, Frachon I, Garcia G, Humbert M, Laurent F, Louis R, Magnan A, Mahut B, Perez T, Roche N, Tillie-Leblond I, Tunon de Lara M, and Dusser D: Update on the roles of distal airways in asthma. Eur Respir Rev. 2009;18:80-95.
31. Contoli M, Bousquet J, Fabbri LM, Magnussen H, Rabe KF, Siafakas NM, Hamid Q, and Kraft M: The small airways and distal lung compartment in asthma and COPD: a time for reappraisal. Allergy. 2010;65:141-151.
32. Ketchell RI, Jensen MW, Spina D, and O'Connor BJ: Doserelated effects of formoterol on airway responsiveness to adenosine 5'-monophosphate and histamine. Eur Respir J. 2002;19:611-616. (Pubitemid 34285156)
33. Luijk B, Kempsford RD, Wright AM, Zanen P, and Lammers J-WJ: Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction. Eur Respir J. 2004;23:559-564. (Pubitemid 38455997)
34. Adams NP, Bestall JC, Jones P, Lasserson TJ, Griffiths B, and Cates CJ: Fluticasone at different doses for chronic asthma in adults and children. Cochrane Database Syst Rev. 2009;(2): CD003534.
35. AstraZeneca UK Ltd.: Symbicort Turbohaler 100/6, Inhalation powder. Summary of Product Characteristics. 2010. http://www.medicines.org.uk/. Accessed January 2011.
36. Politiek MJ, Boorsma M, and Aalbers R: Comparison of formoterol, salbutamol and salmeterol in methacholineinduced severe bronchoconstriction. Eur Respir J. 1999;13: 988-992. (Pubitemid 29288919)
37. Palmqvist M, Arvidsson P, Beckman O, Peterson S, and Lotvall J: Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther. 2001;14:29-34. (Pubitemid 32158294)
38. Berger WE: The use of inhaled formoterol in the treatment of asthma. Ann Allergy Asthma Immunol. 2006;97:24-33. (Pubitemid 44156333)
39. Expert Panel Report: Guidelines for the diagnosis and management of asthma: Expert Panel Report 2. National Asthma Education and Prevention Program: National Institutes of Health, National Heart Lung and Blood Institute. Publication No. 97-4051. 1997. Available from: http://www.nhlbi.nih.gov/ guidelines/asthma/. Accessed 2011.
40. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, and Wanger J: Standardisation of spirometry. Eur Respir J. 2005;26: 319-338. (Pubitemid 41079078)
41. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, and Yernault JC: Lung volumes and forced ventilatory flows. Eur Respir J Suppl. 1993;16:5-40. (Pubitemid 23116782)
42. Polgar G, and Promdhat V: Pulmonary Function Testing in Children: Techniques and Standards. W. B. Saunders Co., Philadelphia, PA; 1971.
43. FitzGerald JM, Boulet LP, and Follows RM: The CONCEPT trial: a 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther. 2005;27:393-406. (Pubitemid 40732647)
44. Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martinez-Jimenez NE, and Buhl R: Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract. 2007;61:725-736. (Pubitemid 46587876)
45. McKeage K, and Keam SJ: Salmeterol/fluticasone propionate: a review of its use in asthma. Drugs. 2009;69:1799-1828.
46. Reynolds NA, Lyseng-Williamson KA, and Wiseman LR: Inhaled salmeterol/fluticasone propionate: a review of its use in asthma. Drugs. 2005;65:1715-1734. (Pubitemid 41149029)
47. Rosenhall L, Heinig JH, Lindqvist A, Leegaard J, Stahl E, and Bergqvist PB: Budesonide/formoterol (Symbicort) is well tolerated and effective in patients with moderate persistent asthma. Int J Clin Pract. 2002;56:427-433. (Pubitemid 34855301)
48. Dhillon S, and Keating GM: Beclometasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler. Drugs. 2006;66:1475-1483; discussion 1484-1475.
49. Frois C, Wu EQ, Ray S, and Colice GL: Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol. Clin Ther. 2009;31:2779-2803.
50. Lasserson TJ, Cates CJ, Ferrara G, and Casali L: Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst Rev. 2010;(3):CD004106.
51. Ducharme FM, Ni Chroinin M, Greenstone I, and Lasserson TJ: Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev. 2010; (4):CD005533.
52. Ducharme FM, Ni Chroinin M, Greenstone I, and Lasserson TJ: Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev. 2010;(5):CD005535.
53. Adams NP, Lasserson TJ, Cates CJ, and Jones P: Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev. 2009;(2): CD002310.
54. Molimard M, Le Gros V, Robinson P, and Bourdeix I: Prevalence and associated factors of oropharyngeal side effects in users of inhaled corticosteroids in a real-life setting. J Aerosol Med Pulm Drug Deliv. 2010;23:91-95.
55. Chung KF, Caramori G, and Adcock IM: Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. Eur J Clin Pharmacol. 2009;65:853-871.
56. Stoloff SW, Stempel DA, Meyer J, Stanford RH, and Carranza, Rosenzweig JR: Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol. 2004;113:245-251. (Pubitemid 38210545)
57. Marceau C, Lemiere C, Berbiche D, Perreault S, and Blais L: Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma. J Allergy Clin Immunol. 2006;118:574-581. (Pubitemid 44301411)
58. Delea TE, Stanford RH, Hagiwara M, and Stempel DA: Association between adherence with fixed dose combination fluticasone propionate/salmeterol on asthma outcomes and costs. Curr Med Res Opin. 2008;24:3435-3442.
59. Bodzenta-Lukaszyk A, Dymek A, McAulay K, and Mansikka H: Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. BMC Pulm Med. 2011;11:28.
60. Bender BG, Long A, Parasuraman B, and Tran ZV: Factors influencing patient decisions about the use of asthma controller medication. Ann Allergy Asthma Immunol. 2007;98: 322-328. (Pubitemid 46582122)
61. Harding G, Leidy NK, Meddis D, Kleinman L, Wagner S, and O'Brien CD: Interpreting clinical trial results of patientperceived onset of effect in asthma: methods and results of a Delphi panel. Curr Med Res Opin. 2009;25:1563-1571.